Cannabis composition

Abstract

The invention relates to a method for treating cancer or a symptom associated with cancer. In particular, the present invention relates to a method for treating cancer or a symptom associated with cancer, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition comprising a Cannabis extract that comprises Δ9-tetrahydrocannabinol (THC) in an amount of from 50% to 99% by weight of the pharmaceutical composition.

1 . A pharmaceutical composition comprising a  Cannabis  extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the  Cannabis  extract comprising a cannabinoid fraction and a terpene fraction, wherein the  Cannabis  extract comprises either:
 A:
 ≥0.3% w/w of the terpene fraction; 
 ≥50% w/w Δ 9 -Tetrahydrocannabinol (THC); 
 ≥0.3% w/w Cannabigerol (CBG); and 
 ≤0.5% w/w Cannabinodiol (CBN). 
   or   B:
 ≥0.5% w/w of the terpene fraction; 
 ≥60% w/w CBD; 
 ≤3% w/w THC; and 
 ≤0.1% w/w CBN; 
   
       wherein the terpene fraction comprises:
 β-caryophyllene in an amount of at least 11% by weight of the terpene fraction, and 
 one or more of:
 linalool in an amount of at least 5% by weight of the terpene fraction; and 
 β-pinene in an amount of at least 1% by weight of the terpene fraction. 
 
 
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein the  Cannabis  extract is a  Cannabis  oil. 
     
     
         3 . The pharmaceutical composition according to  claim 1  or  2 , wherein the  Cannabis  extract comprises Δ 9 -tetrahydrocannabinol (THC) in an amount of from 50% to 99% by weight of the pharmaceutical composition. 
     
     
         4 . The pharmaceutical composition according to  claim 1  or  2 , comprising cannabidiol (CBD) in an amount of from 60% to 99% by weight of the pharmaceutical composition. 
     
     
         5 . The pharmaceutical composition according to any one of  claims 1  to  4 , wherein the  Cannabis  extract comprises one or more additional cannabinoids selected from Δ 9 -Tetrahydrocannabinolic acid (THCA), Δ 9 -Tetrahydrocannabivarin (THCV), and (-)-Cannabidivarin (CBDV). 
     
     
         6 . The pharmaceutical composition according to any one of  claims 1  to  5 , wherein the terpene fraction comprises both linalool and β-pinene. 
     
     
         7 . The pharmaceutical composition according to any one of  claims 1  to  6 , wherein the terpene fraction further comprises one or more of β-myrcene, D-limonene, a nerolidol and α-pinene. 
     
     
         8 . The pharmaceutical composition according to any one of  claims 1  to  7 , wherein the terpene fraction further comprises one or more of oc-bisabolol, caryophyllene oxide, p-cymene, isopulegol, ocimene, α-terpinene, γ-terpinene, δ-s-carene, guaiol, and terpinolene. 
     
     
         9 . The pharmaceutical composition according to any one of  claims 1  to  8 , wherein the pharmaceutically acceptable carrier is sesame oil. 
     
     
         10 . The pharmaceutical composition according to any one of  claims 1  to  9 , further comprising an active agent other than the  Cannabis  extract. 
     
     
         11 . A method for treating cancer or a symptom associated with cancer, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to any one of  claims 1  to  10 . 
     
     
         12 . The method according to  claim 11 , wherein the cancer is breast cancer. 
     
     
         13 . The method according to  claim 12 , wherein the cancer is selected from HER2 positive, triple negative and hormone receptor positive breast cancer. 
     
     
         14 . Use of a  Cannabis  extract in the preparation of a medicament for treating cancer or a symptom associated with cancer, wherein the  Cannabis  extract comprises a cannabinoid fraction and a terpene fraction, and wherein the  Cannabis  extract comprises either:
 A:
 ≥0.3% w/w of the terpene fraction; 
 ≥50% w/w Δ 9 -Tetrahydrocannabinol (THC); 
 ≥0.3% w/w Cannabigerol (CBG); and 
 ≤0.5% w/w Cannabinodiol (CBN). 
   or   B:
 ≥0.5% w/w of the terpene fraction; 
 ≥60% w/w CBD; 
 ≤3% w/w THC; and 
 ≤0.1% w/w CBN. 
   
     
     
         15 . The use of  claim 14 , wherein the terpene fraction comprises:
 β-caryophyllene in an amount of at least 11% by weight of the terpene fraction, and   one or more of:
 linalool in an amount of at least 5% by weight of the terpene fraction; and 
 β-pinene in an amount of at least 1% by weight of the terpene fraction. 
   
     
     
         16 . The pharmaceutical composition according to any one of  claims 1  to  10  for treating cancer or a symptom associated with cancer.